Opaleye Management Inc.

October 1, 2026

Alpha Cognition Releases 180-Day Data on CONVERGE Program. Alpha Cognition has published results from a 180‑day study of its CONVERGE program. The data covers patients who are taking ZUNVEYL, donepezil, galantamine or rivastigmine. The release gives a clearer view of how the program performs in real‑world use. Investors can use the information to assess the company’s therapeutic strategy.

September 30, 2026

Sol-Gel Technologies Announces Investor Day for SGT-610. Sol-Gel Technologies has announced it will host a KOL Investor Day for its SGT-610 product on October 14, 2026. The event will bring together key opinion leaders to discuss the product's progress and future plans. Investors can expect additional details on SGT-610’s development and potential market impact.

October 14, 2026

Eton Secures U.S. License for LIBERVANT Buccal Film. Eton Pharmaceuticals has signed an exclusive U.S. license and supply agreement with Aquestive Therapeutics for LIBERVANT, a buccal film designed to treat seizure clusters in epilepsy patients. The partnership will bring the product to market in April 2027, expanding Eton’s epilepsy portfolio. The deal positions Eton to capture a niche therapeutic area and could support future revenue growth.

October 14, 2026

Harrow (HROW) gains analyst support and conference buzz amid turnaround focus. Recent coverage highlights growing attention on Harrow’s ophthalmic pipeline, with analysts maintaining a $63 price target and an average target of $65. A recent conference has generated buzz, while options activity suggests market participants are watching the stock closely. The company’s Q3 results are expected to confirm whether the turnaround plan is taking hold.

September 28, 2026

Codexis Signs siRNA Manufacturing Deal. Codexis has entered an agreement with an unnamed siRNA drug innovator to use its ECO Synthesis platform for stereo-defined fragment synthesis. This partnership highlights the company's manufacturing capabilities in a growing therapeutic area. The stock is currently trading near its 52-week low, with recent price action showing rejection at support levels.